Tag: Virus

Eliminating hepatitis B: Bridging research, policy, and practice

Clinical Associate Professor, Shevanthi Nayagam

On World Hepatitis Day, Clinical Associate Professor, Dr Shevanthi Nayagam, working across the School of Public Health and Department of Metabolism, Digestion, and Reproduction, shares how her research is helping shape global and national strategies to eliminate hepatitis B (HBV). From modelling vaccine impact to supporting birth dose policies in Africa, she highlights the power of evidence, collaboration, and local action in tackling this silent epidemic. 

Hepatitis B is a virus that attacks the liver and, over time, can cause serious complications such as cirrhosis and liver cancer. What makes it particularly dangerous is that many people don’t realise that they are infected – it can silently damage the liver for years without causing symptoms.  

One of the things that motivated me to start research in hepatitis B over a decade ago, was just how little attention this virus received, despite affecting 254 million people. In 2022 it was estimated to have caused 1.1 million deaths. I’ve seen how hepatitis B continues to affect the lives of those living with the infection and their families – particularly in low- and middle-income countries where prevention, diagnosis and treatment are often out of reach.  

My translational research sits at the intersection of clinical epidemiology, modelling, and health economics – all aimed at an overarching goal: supporting countries to eliminate viral hepatitis through evidence-based decision making. 

A big part of my work involves connecting the global with the local. This dual approach helps ensure that international recommendations are grounded in real-world data . Of course, this kind of work isn’t done in isolation. Everything we do depends on strong collaboration with a wide range of partners – including clinicians, scientists, ministries of health, policy makers and funding agencies. 

(more…)

The complex relationship between viruses and our immune system

Prof John TregoningVirus Appreciation Day, celebrated annually on 3 October, serves a dual purpose: to foster respect and understanding for viruses while raising awareness about their serious impacts on health. To mark the day, Professor John Tregoning from Imperial’s Department of Infectious Disease shares valuable insights into influenza viruses, highlighting their effects, the importance of vaccination, and ongoing research for universal vaccines against evolving strains in our latest blog.

Viruses have an enormous impact on human health, but they don’t only infect humans. Many viruses also infect animals, plants and even bacteria. Some viruses are quite promiscuous, infecting a wide range of animal species before passing on to humans through a process known as zoonotic transmission. One of the most problematic of these zoonotic infections is influenza virus.  

The main natural reservoir of influenza virus is wild birds, particularly ducks and geese. The virus can then transmit from these birds into domestic poultry, like chickens, and to livestock, such as pigs, before ultimately reaching people. In the past five years, a new strain of avian influenza has emerged with an ability to infect an even wider range of mammalian species. It has been detected in cattle in the US.  

Influenza, the disease caused by the virus, poses a substantial health burden. It resulted in nearly 15,000 deaths in the UK in the 2022-23 winter season. As well as death, it is a significant cause of hospitalisation and general illness – with a long tail of recovery. Additionally, influenza infection doubles the risk of heart attacks and strokes for up to a year after illness. Given these risks, getting an influenza vaccine this time of year is highly recommended. As I discovered researching my latest book Live Forever one of the simplest ways of extending your life is through vaccination. A vaccine will give you protection against the most severe forms of disease caused by the virus and protect you against subsequent illness.Vaccines train your body to recognise pathogens and fight them off. To do this, they make use of a facet of immunity called immune memory. When re-exposed to the same virus, your immune response activates faster and stronger, stopping the infection in its tracks. Several aspects of immune memory can prevent subsequent infections, but an important one are antibodies – this is a type of protein that is highly specific in what it can recognise and bind. When you are immunised with influenza vaccine, you make influenza virus specific antibodies that can stop the virus from infecting you. 

(more…)

What is the new coronavirus (2019-nCoV) and what do we know about the outbreak so far?

This post was last updated on 31 January 2020

What is the ‘Wuhan coronavirus (2019-nCoV)’ and what do we know about it so far?
Dr John Tregoning (JT) from Imperial’s Department of Infectious Disease spoke to the School of Public Health’s Prof Steven Riley (SR) about the coronavirus outbreak that recently began in Wuhan, China.

Who has been working on the outbreak epidemiology at Imperial College London?

SR: I work as part of the MRC Centre for Global Infectious Disease  Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics centre with Prof Neil Ferguson, Dr Natsuko Imai, Dr Ilaria Dorigatti, Dr Anne Cori Prof Christl Donnelly, Prof Azra Ghani and Dr Marc Baguelin.

So what is this new coronavirus?

SR: It is a viral infection that was first discovered in the Chinese city of Wuhan in 2019 that has been associated with a number of cases of pneumonia – an infection of the tissue in the lungs. You might see it being called ‘2019-nCoV’, which stand for novel (or new) coronavirus. More information has been provided by the World Health Organisation. (more…)

Hope for a hepatitis B cure: the cunning virus that is outsmarting scientists

For World Hepatitis Day, Dr Ana Ortega-Prieto explains why she switched her research focus from hepatitis C to hepatitis B – a virus that continues its global spread despite an available vaccine. 

When I first started to work on hepatitis C virus (HCV) for my PhD, the general conviction was that it was a dangerous pathogen with very unsuccessful treatments. In the past years, this has completely changed; patients used to endure one year of treatment with severe side effects, but can now expect just three months of treatment, which is generally well tolerated. The truly impressive part here is that treatment success went up from below 50% to well over 90%. This has triggered the World Health Organisation (WHO) to aim for the eradication of all viral hepatitis by 2030 – a very ambitious goal. (more…)